Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure

Journal of Cardiovascular Pharmacology

Volumn 30, Issue 2, 1997, Pages 253-260

  Bellissant, Eric ^a,b   Chau, Nguyen Phong ^c   Thuillez, Christian ^a   Gerbeau, Christophe ^d   Richard, Christian ^a   Giudicelli, Jean François ^a  

^a BICÊTRE HOSPITAL   (France)

^b Inst de Rech Contre le Cancer IRCC   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Laboratoires Sandoz   (France)

Author keywords

Concentration; Congestive heart failure; Effect compartment; Effect relation; Hemodynamics; PK PD modeling; Sigmoid model; Spiraprilat

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; SPIRAPRIL; SPIRAPRILAT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; ENZYME ACTIVITY; HUMAN; LUNG CAPILLARY PRESSURE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VASCULAR RESISTANCE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENALAPRIL; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; PEPTIDYL-DIPEPTIDASE A; PULMONARY CIRCULATION; PULMONARY WEDGE PRESSURE; REGIONAL BLOOD FLOW; VASCULAR RESISTANCE;

EID: 0342601067     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199708000-00016     Document Type: Article

References (24)

1. Kelman AW, Reid JL, Millar JA. Concentration effect modelling with converting enzyme inhibitors in man. Br J Clin Pharmacol 1983;15:506-7.
2. Lees KR, Kelman AW, Reid JL. Effect of repeated dosing on concentration-effect relationships with the angiotensin converting enzyme inhibitor, perindopril. Br J Clin Pharmacol 1986;22:234P.
3. Johnston CI, Jackson B, McGrath B, Matthews G, Arnolda L. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition. J Hypertens 1983;1(suppl 1):71-5.
4. Donnelly R, Meredith PA, Elliott HL, Reid JL. Kinetic-dynamic relations and individual responses to enalapril. Hypertension 1990; 15:301-9.
5. Cody RJ, Covit A, Schaer G, Williams G. Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe chronic congestive heart failure. Am Heart J 1982;104:1180-3.
6. Shaw TRD, Duncan FM, Williams BC, et al. Plasma free captopril concentrations during short and long term treatment with oral captopril for heart failure. Br Heart J 1985;54:160-5.
7. Dickstein K. Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. J Cardiovasc Pharmacol 1987;9(suppl 3):S73-81.
8. Dickstein K, Till AE, Aarsland T, et al. The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. Br J Clin Pharmacol 1987;23:403-10.
9. Hof RP, Novosel D, Evenou JP, Hof A. Autonomic nervous system dysfunction alters drug effects: implications for testing drugs for the treatment of heart failure. J Cardiovasc Pharmacol 1992; 20: 125-30.
10. Bellissant E, Annane D, Pussard E, Thuillez C, Giudicelli JF. Systemic, pulmonary, brachial, renal and hepato-splanchnic hemodynamic effects of spirapril in severe congestive heart failure. Fundam Clin Pharmacol 1996;10:127-35.
11. Safar ME, Peronneau PA, Levenson JA, Toto-Moukouo JA, Simon AC. Pulsed Doppler: diameter, blood flow velocity and volumic flow of the brachial artery in sustained essential hypertension. Circulation 1981;63:393-400.
12. Cushman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 1971;20:1637-48.
13. Hossein-Nia M, Surve AH, Weglein R, Gerbeau C, Holt DW. Radioimmunoassays for spirapril and its active metabolite spiraprilat: performance and application. Ther Drug Monit 1992;14:234-42.
14. Siphar An integrated computer system for pharmacokinetic data analysis: user's manual release 3.3. Créteil: Simed, 1989.
15. Bellissant E, Chau NP, Giudicelli JF. A computer program for kinetic-dynamic modeling in non steady-state experiments [Abstract] Clin Pharmacol Ther 1996;59:147.
16. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d -tubocurarine. Clin Pharmacol Ther 1979;25:358-71.
17. Unadkat JD, Bartha F, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin Pharmacol Ther 1986;40:86-93.
18. Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical recipes: the art of scientific computing. Cambridge: Cambridge University Press, 1986.
19. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia: Lea & Febiger, 1980.
20. Bellissant E, Chau NP, Giudicelli JF. Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. J Cardiovasc Pharmacol. 1996;28:470-8.
21. Bellissant E, Chau NP, Thuillez C, Giudicelli JF. Modélisation de la relation entre concentration plasmatique du métabolite actif du perindopril et inhibition de l'activité de l'enzyme de conversion plasmatique chez le volontaire sain. Arch Mal Coeur 1990;83: 1285-9.
22. Witte PU, Irmisch R, Hajdu P, Metzger H. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. Eur J Clin Pharmacol 1984;27:577-81.
23. Francis RJ, Brown AN, Kler L, et al. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol 1987;9:32-8.
24. MacDonald NJ, Hughes DM, Lees KR, Reid JL. Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man. Br J Clin Pharmacol 1990;30:107-13.